These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32338410)

  • 1. Seamless phase 2/3 oncology trial design with flexible sample size determination.
    Teng Z; Tian Y; Liu Y; Liu G
    Stat Med; 2020 Aug; 39(18):2373-2386. PubMed ID: 32338410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS).
    Teng Z; Liang L; Liu G; Liu Y
    Stat Med; 2018 Dec; 37(28):4097-4113. PubMed ID: 30084110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adaptive seamless Phase 2-3 design with multiple endpoints.
    Jin M; Zhang P
    Stat Methods Med Res; 2021 Apr; 30(4):1143-1151. PubMed ID: 33588655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flexible seamless 2-in-1 design with sample size adaptation.
    Li R; Wu L; Liu R; Lin J
    J Biopharm Stat; 2024 Mar; ():1-19. PubMed ID: 38549502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerate vaccine development using seamless phase 2/3 trial designs.
    Yang JY; Li GC; Yuan Y
    Expert Rev Vaccines; 2024; 23(1):523-534. PubMed ID: 38682812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials.
    Wu C; Liu F; Zhou H; Wu X; Chen C
    Clin Trials; 2021 Dec; 18(6):673-680. PubMed ID: 34693772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
    Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
    BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
    Lin R; Coleman RL; Yuan Y
    J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II.
    Pepić A; Stark M; Friede T; Kopp-Schneider A; Calderazzo S; Reichert M; Wolf M; Wirth U; Schopf S; Zapf A
    Stat Methods Med Res; 2024 Mar; 33(3):433-448. PubMed ID: 38327081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift.
    Mai W; Chow SC
    J Biopharm Stat; 2024 Mar; ():1-14. PubMed ID: 38515269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials.
    Shi H; Yin G
    Stat Methods Med Res; 2018 Jan; 27(1):158-171. PubMed ID: 28034171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimal three-stage design for phase II clinical trials.
    Ensign LG; Gehan EA; Kamen DS; Thall PF
    Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
    Hobbs BP; Barata PC; Kanjanapan Y; Paller CJ; Perlmutter J; Pond GR; Prowell TM; Rubin EH; Seymour LK; Wages NA; Yap TA; Feltquate D; Garrett-Mayer E; Grossman W; Hong DS; Ivy SP; Siu LL; Reeves SA; Rosner GL
    J Natl Cancer Inst; 2019 Feb; 111(2):118-128. PubMed ID: 30561713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extension of 2-in-1 adaptive phase 2/3 designs and its application in oncology clinical trials.
    Fan L; Zhao J; Li W
    Contemp Clin Trials; 2020 Nov; 98():106148. PubMed ID: 32949732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new basket trial design based on clustering of homogeneous subpopulations.
    Krajewska M; Rauch G
    J Biopharm Stat; 2021 Jul; 31(4):425-447. PubMed ID: 34236938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.